Lab experiments indicate that baloxavir (Xofluza), an influenza drug that was approved for US use last year, is active against all four types of flu—A, B, C, and D—and shows activity against many type A viruses of avian and swine origin, according to a new report from the US Centers for Disease Control and Prevention.
The findings, by a team from the CDC and Battelle Memorial institute in Atlanta, are reported today in Emerging Infectious Diseases.
Novel mechanism of action
Read more at CIDRAP…
Jul 9 Emerg Infect Dis report
Oct 24, 2018, CIDRAP News scan on approval of baloxavir
Jul 3 CIDRAP News scan on baloxavir results in children